Nanosonics Limited (OQS) Stock Price & Analysis
OQS Stock Chart & Stats
- Day’s Range
- EUR 1.84 - EUR 1.84
- 52-Week Range
- EUR 1.58 - EUR 2.50
- Previous Close
- EUR 1.82
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 570.67M
- Enterprise Value
- EUR 896.46M
- Total Cash (Recent Filing)
- EUR 155.22M
- Total Debt (Recent Filing)
- EUR 23.13M
- Price to Earnings (P/E)
- 51.4
- Beta
- 0.18
- Next Earnings
- Feb 23, 2027 (Est.)
- EPS Estimate
- 0.01
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Recurring Installed Base
The expanding trophon installed base supports recurring consumables and service revenue, creating a durable annuity stream beyond equipment sales. Continued placements and upgrades can compound utilisation, strengthen customer embeddedness, and provide a foundation for more predictable future cash generation.
Profitability And Cash Generation
Trophon’s strong profitability and cash generation provide internal funding for product development, commercial expansion, and shareholder returns. A profitable core franchise also reduces dependence on CORIS achieving immediate scale, supporting resilience while the newer platform is commercialised.
Conservative Balance Sheet
A debt-free balance sheet and substantial cash reserve give Nanosonics flexibility to fund CORIS, expand capacity, and absorb operating volatility without material financing pressure. This financial strength also supports capital returns while preserving the ability to invest in longer-term growth.
Bears Say
Margin Compression
The decline in net margin indicates that strong gross margins have not fully translated into stable bottom-line profitability. Product mix, currency effects, and rising costs may continue to limit operating leverage, making sustained earnings growth more dependent on execution and revenue scale.
Weaker Cash Conversion
Positive cash generation remains a strength, but the sharp FY2026 deterioration signals less consistent conversion of accounting earnings into cash. If this persists, internally funded investment and capital returns could become less flexible, while working-capital volatility may make financial performance harder to predict.
CORIS Investment Burden
CORIS requires substantial near-term commercial investment before it contributes meaningful revenue, creating a temporary drag on earnings leverage. The mismatch between launch costs and initial sales increases execution risk, particularly if adoption takes longer than management expects to accelerate.
OQS FAQ
What was Nanosonics Limited’s price range in the past 12 months?
What is Nanosonics Limited’s market cap?
When is Nanosonics Limited’s upcoming earnings report date?
How were Nanosonics Limited’s earnings last quarter?
Is Nanosonics Limited overvalued?
Does Nanosonics Limited pay dividends?
What is Nanosonics Limited’s EPS estimate?
How many shares outstanding does Nanosonics Limited have?
What happened to Nanosonics Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Nanosonics Limited?
What is the TipRanks Smart Score and how is it calculated?
Nanosonics Limited Stock Smart Score
Company Description
Nanosonics Limited
Nanosonics Limited, along with its subsidiaries, functions as a global infection prevention enterprise with operations in Australia and beyond. The company focuses on the production and distribution of its trophon ultrasound probe disinfection system, including all related supplies and accessories. Additionally, it dedicates resources to the exploration, development, and market launch of innovative infection control, decontamination products, and their associated technologies. Key offerings from Nanosonics include trophon2, an advanced device for high-level disinfection of ultrasound probes; trophon EPR, a low-temperature, high-level disinfection method specifically for intra-cavity ultrasound probes; and Nanosonics AuditPro, a comprehensive solution for managing compliance with infection control workflows. Established in 2000, Nanosonics Limited is headquartered in Macquarie Park, Australia.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Michael C. Kavanagh
- Employees
- 508
- Website
- www.nanosonics.com.au
- Address
- Building A, Macquarie Park, NSW, 2113, AU
Nanosonics Limited (OQS) Earnings & Revenues
OQS Company Deck
OQS Earnings Call
Earnings Call SentimentPositive
The call presents a predominantly positive operational and financial picture: constant-currency revenue and EBIT growth, strong trophon profitability and cash generation, record placements and upgrades, product innovation (trophon3/trophon2 Plus), solid annuity and service growth, a debt-free balance sheet with substantial cash and an active buyback. Management also delivered substantial regulatory and commercial progress for CORIS and set explicit FY'27 guidance that anticipates continued growth. Negative items are present but largely manageable and/or transitional: a Q3 consumables dip due to weather, margin moderation from product mix and currency, APAC softness tied to rental models, and elevated near-term OpEx to fund CORIS commercialization which will weigh on near-term profitability. Overall, highlights substantially outweigh the lowlights, with CORIS viewed as a meaningful long-term growth opportunity while trophon continues as a strong cash engine.
View all DE:OQS earnings summariesOQS Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 11 | 5 | 6 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 7 | 0 | 5 |
